Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.80 |
| ▸ | PGR | P06401 | 7/20 | 0.80 |
| ▸ | AR | P10275 | 2/20 | 0.74 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4184224 | 0.89 | NR3C1 (1.00) | NR3C1PGRARNR3C2 | |
| SCHEMBL4182458 | 0.87 | NR3C1 (0.92) | NR3C1PGRARNR3C2 | |
| SCHEMBL4184229 | 0.87 | NR3C1 (0.79) | NR3C1PGRARNR3C2 | |
| SCHEMBL4180878 | 0.86 | NR3C1 (1.00) | NR3C1PGRAR | |
| SCHEMBL4183081 | 0.86 | NR3C1 (1.00) | NR3C1PGRARNR3C2 | |
| SCHEMBL7113477 | 0.86 | NR3C1 (0.61) | NR3C1PGRARNR3C2 | |
| SCHEMBL4179935 | 0.85 | NR3C1 (0.74) | NR3C1PGRARNR3C2 | |
| SCHEMBL4183061 | 0.85 | NR3C1 (0.80) | NR3C1PGRARNR3C2 | |
| SCHEMBL4172419 | 0.85 | NR3C1 (1.00) | NR3C1PGRARNR3C2 | |
| SCHEMBL4171493 | 0.85 | NR3C1 (1.00) | NR3C1PGRARNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069427-A1 | Process for the preparation of 5-(substituted)-10 methoxy-2,2,4-trimethyl-2,5-dihydro- 1H-chromeno [3,4-f] quinolines and derivatives thereof | ABBVIE INC. | 2003-04-10 | — | — | US | claimed |
| WO-2003027117-A1 | A PROCESS FOR THE PREPARATION OF 5-(SUBSTITUTED)-10-METHOXY-2,2,4-TRIMETHYL-2,5-DIHYDRO-1H-CHROMENO[3,4-F]QUINOLINES AND DERIVATIVES THEREOF | ABBOTT LABORATORIES (US) | 2003-04-03 | — | — | WO | claimed |
| US-6518430-B1 | The present invention relates to an efficient process for the preparation of 5-(substituted)-10-methoxy-2,2,4-trimethyl-2,5- dihydro-1H-chromeno(3,4-f)quinolines. | ABBOTT LABORATORIES | 2003-02-11 | — | — | US | claimed |
| US-6673930-B2 | PREPARING A SELECTIVE GLUCOCORTICOID RECEPTOR AGENTS BY CYCLIZATION, DEHALOGENATION, AMINATION, ETHERIFICATION, HYDROXYLATION | ABBVIE INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030069427-A1 | Process for the preparation of 5-(substituted)-10 methoxy-2,2,4-trimethyl-2,5-dihydro- 1H-chromeno [3,4-f] quinolines and derivatives thereof | ABBVIE INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2003027117-A1 | A PROCESS FOR THE PREPARATION OF 5-(SUBSTITUTED)-10-METHOXY-2,2,4-TRIMETHYL-2,5-DIHYDRO-1H-CHROMENO[3,4-F]QUINOLINES AND DERIVATIVES THEREOF | ABBOTT LABORATORIES (US) | 2003-04-03 | — | — | WO | disclosed |
| US-6518430-B1 | The present invention relates to an efficient process for the preparation of 5-(substituted)-10-methoxy-2,2,4-trimethyl-2,5- dihydro-1H-chromeno(3,4-f)quinolines. | ABBOTT LABORATORIES | 2003-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069427-A1 | Process for the preparation of 5-(substituted)-10 methoxy-2,2,4-trimethyl-2,5-dihydro- 1H-chromeno [3,4-f] quinolines and derivatives thereof | HTR3C, CYP3A5, NQO2 | NR3C1 4111/4885PGR 3676/4885AR 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.